Literature DB >> 31995636

Posttreatment Symptoms in Lyme Borreliosis.

Klemen Strle1, Franc Strle2.   

Abstract

Keywords:  zzm321990 Borrelia burgdorferi sensu lato; Lyme borreliosis; biomarkers; outcome; posttreatment Lyme disease symptoms

Year:  2020        PMID： 31995636      PMCID： PMC7819510          DOI： 10.1093/cid/ciz1218

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  13 in total

1.  CCL19 as a Chemokine Risk Factor for Posttreatment Lyme Disease Syndrome: a Prospective Clinical Cohort Study.

Authors:  John N Aucott; Mark J Soloski; Alison W Rebman; Lauren A Crowder; Lauren J Lahey; Catriona A Wagner; William H Robinson; Kathleen T Bechtold
Journal:  Clin Vaccine Immunol       Date:  2016-09-06

2.  Comparison of culture-confirmed erythema migrans caused by Borrelia burgdorferi sensu stricto in New York State and by Borrelia afzelii in Slovenia.

Authors:  F Strle; R B Nadelman; J Cimperman; J Nowakowski; R N Picken; I Schwartz; V Maraspin; M E Aguero-Rosenfeld; S Varde; S Lotric-Furlan; G P Wormser
Journal:  Ann Intern Med       Date:  1999-01-05       Impact factor: 25.391

3.  Randomized Trial of Longer-Term Therapy for Symptoms Attributed to Lyme Disease.

Authors:  Anneleen Berende; Hadewych J M ter Hofstede; Fidel J Vos; Henriët van Middendorp; Michiel L Vogelaar; Mirjam Tromp; Frank H van den Hoogen; A Rogier T Donders; Andrea W M Evers; Bart Jan Kullberg
Journal:  N Engl J Med       Date:  2016-03-31       Impact factor: 91.245

4.  Prospective Evaluation of the Frequency and Severity of Symptoms in Lyme Disease Patients With Erythema Migrans Compared With Matched Controls at Baseline, 6 Months, and 12 Months.

Authors:  Gary P Wormser; Donna McKenna; Carol L Karmen; Keith D Shaffer; Jesse H Silverman; John Nowakowski; Carol Scavarda; Eugene D Shapiro; Paul Visintainer
Journal:  Clin Infect Dis       Date:  2020-12-15       Impact factor: 9.079

5.  Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease.

Authors:  M S Klempner; L T Hu; J Evans; C H Schmid; G M Johnson; R P Trevino; D Norton; L Levy; D Wall; J McCall; M Kosinski; A Weinstein
Journal:  N Engl J Med       Date:  2001-07-12       Impact factor: 91.245

6.  Anti-neural antibody reactivity in patients with a history of Lyme borreliosis and persistent symptoms.

Authors:  Abhishek Chandra; Gary P Wormser; Mark S Klempner; Richard P Trevino; Mary K Crow; Norman Latov; Armin Alaedini
Journal:  Brain Behav Immun       Date:  2010-03-18       Impact factor: 7.217

7.  A randomized, placebo-controlled trial of repeated IV antibiotic therapy for Lyme encephalopathy.

Authors:  B A Fallon; J G Keilp; K M Corbera; E Petkova; C B Britton; E Dwyer; I Slavov; J Cheng; J Dobkin; D R Nelson; H A Sackeim
Journal:  Neurology       Date:  2007-10-10       Impact factor: 9.910

8.  Oral doxycycline versus intravenous ceftriaxone for treatment of multiple erythema migrans: an open-label alternate-treatment observational trial.

Authors:  Daša Stupica; Maša Velušcek; Rok Blagus; Petra Bogovic; Tereza Rojko; Tjaša Cerar; Franc Strle
Journal:  J Antimicrob Chemother       Date:  2018-05-01       Impact factor: 5.790

9.  Study and treatment of post Lyme disease (STOP-LD): a randomized double masked clinical trial.

Authors:  L B Krupp; L G Hyman; R Grimson; P K Coyle; P Melville; S Ahnn; R Dattwyler; B Chandler
Journal:  Neurology       Date:  2003-06-24       Impact factor: 9.910

10.  Clinical Course, Serologic Response, and Long-Term Outcome in Elderly Patients with Early Lyme Borreliosis.

Authors:  Katarina Boršič; Rok Blagus; Tjaša Cerar; Franc Strle; Daša Stupica
Journal:  J Clin Med       Date:  2018-12-02       Impact factor: 4.241
View more
  1 in total

1.  Lyme Disease in Humans.

Authors:  Justin D Radolf; Klemen Strle; Jacob E Lemieux; Franc Strle
Journal:  Curr Issues Mol Biol       Date:  2020-12-11       Impact factor: 2.081
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.